International Total Liab vs Inventory Analysis

IBT Stock

694.00 8.00 1.17%

International Biotechnology financial indicator trend analysis is infinitely more than just investigating International Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether International Biotechnology is a good investment. Please check the relationship between International Biotechnology Total Liab and its Inventory accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Total Liab vs Inventory

Total Liab vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of International Biotechnology Total Liab account and Inventory. At this time, the significance of the direction appears to have almost no relationship.

The correlation between International Biotechnology's Total Liab and Inventory is 0.13. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Inventory in the same time period over historical financial statements of International Biotechnology Trust, assuming nothing else is changed. The correlation between historical values of International Biotechnology's Total Liab and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of International Biotechnology Trust are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Total Liab i.e., International Biotechnology's Total Liab and Inventory go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Inventory

Most indicators from International Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into International Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of November 26, 2024, Selling General Administrative is expected to decline to about 1.1 M. In addition to that, Tax Provision is expected to decline to about 129.3 K

International Biotechnology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Other Liab	Cash	Other Assets	Short Term Investments	Total Liab	Common Stock	Accounts Payable	Other Current Liab	Total Current Liabilities	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Current Assets	Short Long Term Debt Total	Other Current Assets	Inventory	Net Tangible Assets
Total Assets		0.99	0.44	-0.16	-0.04	0.43	0.6	0.06	0.03	-0.48	0.01	0.48	0.37	0.28	-0.2	0.22	0.13	-0.6	-0.49	0.19	-0.45	0.1	0.52	-0.18	-0.03	0.54
Total Stockholder Equity	0.99		0.5	-0.17	-0.01	0.49	0.48	0.12	0.01	-0.38	-0.01	0.35	0.32	0.21	-0.13	0.13	0.03	-0.57	-0.48	0.13	-0.46	0.01	0.41	-0.16	-0.06	0.5
Other Liab	0.44	0.5		-0.17	-0.13	0.99	0.01	0.86	-0.01	0.21	-0.06	-0.31	-0.22	-0.73	0.74	-0.01	-0.03	0.11	0.16	-0.25	0.05	0.07	-0.18	0.07	-0.44	-0.31
Cash	-0.16	-0.17	-0.17		0.8	-0.15	0.18	-0.22	-0.1	0.33	-0.26	-0.09	-0.45	0.04	-0.24	0.66	-0.34	-0.24	-0.19	0.67	0.03	0.38	0.13	-0.86	-0.09	0.46
Other Assets	-0.04	-0.01	-0.13	0.8		-0.11	0.06	-0.27	-0.12	0.36	-0.26	-0.15	-0.56	0.1	-0.28	0.52	-0.36	-0.39	-0.38	0.5	0.0	0.22	-0.03	-0.8	-0.01	0.45
Short Term Investments	0.43	0.49	0.99	-0.15	-0.11		-0.02	0.88	-0.07	0.21	-0.12	-0.32	-0.2	-0.74	0.75	0.02	-0.08	0.15	0.19	-0.26	0.05	0.03	-0.18	0.07	-0.48	-0.3
Total Liab	0.6	0.48	0.01	0.18	0.06	-0.02		-0.27	0.09	-0.68	0.05	0.87	0.33	0.45	-0.5	0.65	0.43	-0.54	-0.42	0.58	-0.26	0.56	0.84	-0.38	0.13	0.61
Common Stock	0.06	0.12	0.86	-0.22	-0.27	0.88	-0.27		-0.04	0.33	-0.06	-0.5	-0.21	-0.89	0.91	-0.14	-0.14	0.6	0.62	-0.45	0.2	-0.11	-0.42	0.29	-0.59	-0.58
Accounts Payable	0.03	0.01	-0.01	-0.1	-0.12	-0.07	0.09	-0.04		-0.12	0.98	-0.1	-0.22	0.11	-0.09	-0.24	-0.02	0.04	-0.01	-0.1	-0.4	-0.11	-0.27	-0.04	0.27	-0.11
Other Current Liab	-0.48	-0.38	0.21	0.33	0.36	0.21	-0.68	0.33	-0.12		-0.18	-0.81	-0.55	-0.58	0.52	-0.27	-0.29	0.33	0.28	-0.09	0.45	0.01	-0.66	-0.17	-0.26	-0.44
Total Current Liabilities	0.01	-0.01	-0.06	-0.26	-0.26	-0.12	0.05	-0.06	0.98	-0.18		-0.07	-0.11	0.15	-0.1	-0.35	0.04	0.09	0.03	-0.2	-0.4	-0.18	-0.28	0.12	0.3	-0.17
Net Debt	0.48	0.35	-0.31	-0.09	-0.15	-0.32	0.87	-0.5	-0.1	-0.81	-0.07		0.61	0.68	-0.65	0.44	0.55	-0.49	-0.39	0.43	-0.19	0.41	0.89	-0.08	0.25	0.58
Retained Earnings	0.37	0.32	-0.22	-0.45	-0.56	-0.2	0.33	-0.21	-0.22	-0.55	-0.11	0.61		0.49	-0.39	-0.1	0.3	-0.09	-0.04	0.03	-0.13	-0.09	0.58	0.32	-0.04	0.27
Non Current Assets Total	0.28	0.21	-0.73	0.04	0.1	-0.74	0.45	-0.89	0.11	-0.58	0.15	0.68	0.49		-0.95	0.13	0.14	-0.6	-0.58	0.42	-0.42	0.0	0.55	-0.2	0.48	0.73
Non Currrent Assets Other	-0.2	-0.13	0.74	-0.24	-0.28	0.75	-0.5	0.91	-0.09	0.52	-0.1	-0.65	-0.39	-0.95		-0.28	-0.08	0.63	0.63	-0.56	0.41	-0.09	-0.57	0.38	-0.47	-0.77
Cash And Short Term Investments	0.22	0.13	-0.01	0.66	0.52	0.02	0.65	-0.14	-0.24	-0.27	-0.35	0.44	-0.1	0.13	-0.28		-0.02	-0.35	-0.23	0.61	0.11	0.49	0.63	-0.65	-0.18	0.55
Net Receivables	0.13	0.03	-0.03	-0.34	-0.36	-0.08	0.43	-0.14	-0.02	-0.29	0.04	0.55	0.3	0.14	-0.08	-0.02		-0.14	-0.08	-0.1	0.37	0.71	0.47	0.18	0.35	-0.17
Common Stock Total Equity	-0.6	-0.57	0.11	-0.24	-0.39	0.15	-0.54	0.6	0.04	0.33	0.09	-0.49	-0.09	-0.6	0.63	-0.35	-0.14		0.98	-0.52	0.33	-0.28	-0.59	0.5	-0.41	-0.72
Common Stock Shares Outstanding	-0.49	-0.48	0.16	-0.19	-0.38	0.19	-0.42	0.62	-0.01	0.28	0.03	-0.39	-0.04	-0.58	0.63	-0.23	-0.08	0.98		-0.44	0.35	-0.18	-0.47	0.44	-0.47	-0.63
Non Current Liabilities Total	0.19	0.13	-0.25	0.67	0.5	-0.26	0.58	-0.45	-0.1	-0.09	-0.2	0.43	0.03	0.42	-0.56	0.61	-0.1	-0.52	-0.44		-0.19	0.35	0.5	-0.72	0.17	0.67
Other Stockholder Equity	-0.45	-0.46	0.05	0.03	0.0	0.05	-0.26	0.2	-0.4	0.45	-0.4	-0.19	-0.13	-0.42	0.41	0.11	0.37	0.33	0.35	-0.19		0.41	-0.01	0.07	-0.17	-0.51
Total Current Assets	0.1	0.01	0.07	0.38	0.22	0.03	0.56	-0.11	-0.11	0.01	-0.18	0.41	-0.09	0.0	-0.09	0.49	0.71	-0.28	-0.18	0.35	0.41		0.52	-0.45	0.16	0.11
Short Long Term Debt Total	0.52	0.41	-0.18	0.13	-0.03	-0.18	0.84	-0.42	-0.27	-0.66	-0.28	0.89	0.58	0.55	-0.57	0.63	0.47	-0.59	-0.47	0.5	-0.01	0.52		-0.27	0.09	0.63
Other Current Assets	-0.18	-0.16	0.07	-0.86	-0.8	0.07	-0.38	0.29	-0.04	-0.17	0.12	-0.08	0.32	-0.2	0.38	-0.65	0.18	0.5	0.44	-0.72	0.07	-0.45	-0.27		-0.17	-0.55
Inventory	-0.03	-0.06	-0.44	-0.09	-0.01	-0.48	0.13	-0.59	0.27	-0.26	0.3	0.25	-0.04	0.48	-0.47	-0.18	0.35	-0.41	-0.47	0.17	-0.17	0.16	0.09	-0.17		0.06
Net Tangible Assets	0.54	0.5	-0.31	0.46	0.45	-0.3	0.61	-0.58	-0.11	-0.44	-0.17	0.58	0.27	0.73	-0.77	0.55	-0.17	-0.72	-0.63	0.67	-0.51	0.11	0.63	-0.55	0.06

Click cells to compare fundamentals

International Biotechnology Account Relationship Matchups

International Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	302.7M	347.8M	326.9M	304.9M	308.2M	204.7M
Total Stockholder Equity	283.9M	323.8M	284.9M	270.3M	282.3M	193.5M
Cash	886K	324K	1.6M	0.0	10.4M	11.0M
Other Assets	116K	97K	146K	248K	308.2M	323.6M
Total Liab	18.8M	24.1M	42.0M	34.6M	25.9M	27.2M
Accounts Payable	715K	1.6M	1.2M	143K	1.9M	1.8M
Other Current Liab	(18.8M)	(23.5M)	(41.2M)	(32.6M)	(1.9M)	(2.0M)
Total Current Liabilities	124K	2.2M	1.2M	143K	164.5K	156.2K
Net Debt	17.8M	20.3M	40.0M	32.5M	12.4M	8.8M
Retained Earnings	221.6M	252.1M	213.2M	198.6M	(54.0M)	(51.3M)
Non Current Assets Total	302.2M	345.3M	313.4M	301.9M	297.5M	210.9M
Non Currrent Assets Other	(302.2M)	(345.3M)	(313.4M)	(301.9M)	(297.5M)	(312.4M)
Cash And Short Term Investments	886K	324K	1.6M	10.4M	12.0M	12.6M
Net Receivables	45K	845K	13.3M	2.7M	99K	94.1K
Common Stock Shares Outstanding	38.5M	40.5M	41.1M	40.6M	38.2M	38.0M
Liabilities And Stockholders Equity	302.7M	347.8M	326.9M	304.9M	308.2M	218.2M
Non Current Liabilities Total	18.1M	21.9M	1.2M	32.5M	37.3M	39.2M
Other Stockholder Equity	229.2M	(242.2M)	(265.9M)	61.4M	29.9M	23.3M
Total Current Assets	369K	2.4M	13.3M	2.7M	10.6M	11.2M
Other Current Assets	163.0K	141K	214K	283K	(10.5M)	(10.0M)
Net Tangible Assets	239.6M	283.9M	323.8M	284.9M	327.6M	282.9M
Long Term Investments	302.2M	345.3M	313.4M	301.9M	297.5M	302.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in International Stock

Balance Sheet is a snapshot of the financial position of International Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. International Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of International Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which International currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

International Total Liab vs Inventory Analysis

Total Liab vs Inventory

Total Liab vs Inventory Correlation Analysis

Correlation Coefficient

Total Liab

Inventory

International Biotechnology fundamental ratios Correlations

International Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

International Biotechnology fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in International Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Short Term Investments	+ 0.99	Other Liab
Total Current Liabilities	+ 0.98	Accounts Payable
Common Stock Shares Outstanding	+ 0.98	Common Stock Total Equity
Non Currrent Assets Other	+ 0.91	Common Stock
Short Long Term Debt Total	+ 0.89	Net Debt

Non Currrent Assets Other	- 0.95	Non Current Assets Total
Non Current Assets Total	- 0.89	Common Stock
Other Current Assets	- 0.86	Cash
Net Debt	- 0.81	Other Current Liab
Other Current Assets	- 0.8	Other Assets
Net Tangible Assets	- 0.77	Non Currrent Assets Other